Lupus & antiphospholipid syndrome
Clinical outcomes of anifrolumab after belimumab failure in systemic lupus erythematosus: A single-center case series
Authors' conclusion
In this exploratory case series, switching from belimumab to anifrolumab was associated with clinical improvement among selected patients with SLE. Certain clinical features, including active skin or neuropsychiatric manifestations and anti-ribonucleoprotein antibody positivity, were more frequently observed among patients who showed improvement after switching therapy.
Study context
- Population
- Female patients with systemic lupus erythematosus (SLE) with inadequate response to belimumab, mostly young with active mucocutaneous manifestations; real-world single-centre settingall female
- Participants
- 8 patients
- Outcome
- LLDAS attainment during follow-up after switching from belimumab to anifrolumab
- Follow-up
- During
Methodological detailssingle-centre, descriptive, exploratory
- Single-centre
- Descriptive
- Exploratory
Main finding
As reported in the abstract
- Patients achieving lupus low disease activity state (LLDAS) during follow-up
- 5
Observational data: associations, not effects.
Original publication
Clinical outcomes of anifrolumab after belimumab failure in systemic lupus erythematosus: A single-center case series. Lupus. Published 13 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →